International Journal of Drug Policy
August 21, 2026
Renae Fomiatti, Helen Keane, Gemma Nourse et al.
Trauma has a become a dominant causal explanation in psychological and public health accounts of drug use, with drug consumption typically framed as a coping response or form of self-medication. Drawing on Lauren Berlant's work (2008, 2011), particularly their concepts of genre, crisis ordinariness and lateral agency, we examine the affective and political conventions of trauma as a genre for...
Psychedelics
August 15, 2026
Khaleel Rajwani
Recent interdisciplinary scholarship has demonstrated how systemic racism, racialized mental health disparities, and histories of colonial and biomedical violence shape psychedelic experiences, therapeutic outcomes, and processes of integration. Emerging literature has foregrounded concerns including racial underrepresentation in research, the violent legacy of the War on Drugs, systemic racism...
Social Identities
August 14, 2026
Jon Stratton
Idiot dancing is a British term. It was mostly used between the late 1960s and the mid-to-late 1970s. It referred to an extreme form of what I am calling here expressive dancing. Expressive dancing refers to dancing that is lacking, or almost lacking, in any choreography. Rather, expressive dancing is dancing where the dancer responds to the beat, other embellishments from the drummer and...
Life
August 14, 2026
Szabolcs Kéri
Clinical trials and naturalistic studies describe psychedelics under markedly different exposure conditions. This narrative review searched PubMed/MEDLINE, the Cochrane Library, ClinicalTrials.gov, and regulatory sources through 15 July 2026, and examined safety and outcomes across four dimensions of exposure: dose, frequency, person, and context. In screened adults receiving one to three...
August 11, 2026
Frances Clemente
Abstract Chapter 2, ‘Religion’, provides an account of mystical ecstasy in the period under investigation, pointing to its ambiguous status and the ways it embodied a modern and disquieting form of religious experience. It shows how the disorderly traits associated with ecstatic phenomena led the Catholic establishment to adopt an ambivalent attitude towards them. It highlights that such an...
Zenodo (CERN European Organization for Nuclear Research)
August 11, 2026
Saanvi Gutta
preprint
Depression affects over 280 million people worldwide and remains one of the leading causes of disability and suicide. Existing treatments such as SSRIs and traditional psychotherapy often fail to provide relief, especially for individuals with treatment‑resistant depression. Recent clinical trials suggest that psychedelic‑assisted therapy using psilocybin or MDMA may offer rapid and durable...
Pharmaceuticals
August 7, 2026
Ouwais Aljabasini, Niki Tagkalidou, Martalu D. Pazos et al.
Background/Objectives: Synthetic cathinones are a rapidly evolving class of new psychoactive substances whose structural diversity complicates toxicological risk assessment. Methylenedioxy cathinones occupy a pharmacological space between MDMA-like entactogens and more dopaminergic stimulant cathinones, but their direct cardiac liabilities remain poorly characterized. This study aimed to...
European Journal of Endocrinology
August 1, 2026
Liv-Helen Lang, Sara-Jessica Camerin, Michelle Müller et al.
Patients with arginine vasopressin (AVP) deficiency (formerly central diabetes insipidus) often report social and emotional deficits and heightened anxiety. Growing evidence suggests that these symptoms may, at least partly, reflect concomitant OXT deficiency. OXT plays a key role in increasing empathy and improving emotion recognition. This analysis aimed to examine empathy and emotion...
International Journal of Drug Policy
August 1, 2026
Myfanwy Graham, Yimin Ge, Rosalie Liccardo Pacula et al.
1 citation
We know little about the extent psychedelic substances are consumed therapeutically and/or discussed with medical professionals despite renewed global interest in these substances. We examined self-reported responses from the 2023 International Cannabis Policy Study (ICPS) in repeated cross-sectional surveys in Canada, the United States, Australia, and New Zealand. The survey included questions...
CNS & Neurological Disorders - Drug Targets
July 31, 2026
Sampriti Paul, Sonal Dubey, Mayur Yergeri Chandrasekharappa et al.
Recent advances in neuropsychopharmacology have renewed interest in psychedelics and entactogens as potential treatments for brain disorders, owing to their rapid effects on neural plasticity, cognition, and affect. Classical serotonergic psychedelics primarily act as 5-HT2A receptor agonists with additional activity at 5-HT1A and other serotonin receptors, whereas entactogens such as MDMA...